Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2020

The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Three months ended June 30, 2020										Three months ended June 30, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	4,504	$	—	$	4,504	$	6,249	$	—	$	6,249
Research and development revenue	3,002		7,461		10,463		4,340		1,730		6,070
Total revenues	7,506		7,461		14,967		10,589		1,730		12,319
Costs and operating expenses:
Cost of product revenue	1,699		—		1,699		2,772		—		2,772
Research and development⁽¹⁾	4,997		5,490		10,487		5,134		2,856		7,990
Selling, general and administrative⁽¹⁾	2,375		621		2,996		2,362		561		2,923
Total segment costs and operating expenses	9,071		6,111		15,182		10,268		3,417		13,685
Income (loss) from operations	$	(1,565)	$	1,350	$	(215)	$	321	$	(1,687)	$	(1,366)
Corporate costs ⁽²⁾					(5,316)						(4,698)
Depreciation and amortization					(506)						(427)
Loss before income taxes					$	(6,037)					$	(6,491)

(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.


	Six months ended June 30, 2020										Six months ended June 30, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	9,604	$	—	$	9,604	$	14,236	$	—	$	14,236
Research and development revenue	8,775		11,258		20,033		6,440		7,225		13,665
Total revenues	18,379		11,258		29,637		20,676		7,225		27,901
Costs and operating expenses:
Cost of product revenue	4,240		—		4,240		7,163		—		7,163
Research and development⁽¹⁾	10,693		10,415		21,108		9,576		6,172		15,748
Selling, general and administrative⁽¹⁾	4,720		1,213		5,933		4,463		1,078		5,541
Total segment costs and operating expenses	19,653		11,628		31,281		21,202		7,250		28,452
Loss from operations	(1,274)		(370)		(1,644)		(526)		(25)		(551)
Corporate costs ⁽²⁾					(11,042)						(10,271)
Depreciation and amortization					(998)						(802)
Loss before income taxes					$	(13,684)					$	(11,624)

(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following tables provides stock-based compensation expense included in loss from operations (in thousands):


	Three months ended June 30,
	2020														2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	741	$	252	$	946	$	1,939	$	601	$	197	$	1,190	$	1,988

	Six months ended June 30,
	2020														2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	1,496	$	494	$	2,118	$	4,108	$	1,237	$	338	$	2,476	$	4,051

Schedule of customers that contributed 10% or more of total accounts receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three Months Ended June 30,			Six Months Ended June 30,
	2020	2019	2020	2019
Customer A	16%	35%	20%	38%
Customer B	12%	14%	11%	26%
Customer C	*	11%	*	*
Customer D	*	*	13%	*
Customer E	38%	*	27%	*

Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	June 30, 2020		December 31, 2019
Customer A	26	%	38	%
Customer B	11	%	10	%
Customer D	30	%	*
Customer F	10	%	*

* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended June 30,						Six months ended June 30,
	2020		2019		2020		2019
Revenues
Americas	$	6,906	$	4,076	$	12,131	$	6,913
EMEA	3,314		4,741		9,285		12,466
APAC	4,747		3,502		8,221		8,522
Total revenues	$	14,967	$	12,319	$	29,637	$	27,901

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):


Long-lived assets	June 30, 2020		December 31, 2019
United States	$	6,822	$	6,282

Schedule of intangible assets and goodwill

Identifiable goodwill was as follows (in thousands):


	As of June 30, 2020 and December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241